80 related articles for article (PubMed ID: 27380317)
1. Efficacy of a specific polyclonal equine F(ab')2 against avian influenza (H5N1) in ferrets: synergy with oseltamivir.
Herbreteau CH; Denizot M; Lowther S; Riddell S; Frazer L; Haining J; Arkinstall R; Payne J; Harper J; Johnson D; Pasquier A; Middleton D; Saluzzo JF
Immunotherapy; 2016 Sep; 8(9):1021-32. PubMed ID: 27380317
[TBL] [Abstract][Full Text] [Related]
2. Passive immunotherapy for influenza A H5N1 virus infection with equine hyperimmune globulin F(ab')2 in mice.
Lu J; Guo Z; Pan X; Wang G; Zhang D; Li Y; Tan B; Ouyang L; Yu X
Respir Res; 2006 Mar; 7(1):43. PubMed ID: 16553963
[TBL] [Abstract][Full Text] [Related]
3. Cross clade prophylactic and therapeutic efficacy of polyvalent equine immunoglobulin F(ab')2 against highly pathogenic avian influenza H5N1 in mice.
Zhao Z; Yan F; Chen Z; Luo D; Duan Y; Yang P; Li Z; Peng D; Liu X; Wang X
Int Immunopharmacol; 2011 Dec; 11(12):2000-6. PubMed ID: 21906698
[TBL] [Abstract][Full Text] [Related]
4. Oseltamivir prophylactic regimens prevent H5N1 influenza morbidity and mortality in a ferret model.
Boltz DA; Rehg JE; McClaren J; Webster RG; Govorkova EA
J Infect Dis; 2008 May; 197(9):1315-23. PubMed ID: 18422444
[TBL] [Abstract][Full Text] [Related]
5. The Hemagglutinin A Stem Antibody MEDI8852 Prevents and Controls Disease and Limits Transmission of Pandemic Influenza Viruses.
Paules CI; Lakdawala S; McAuliffe JM; Paskel M; Vogel L; Kallewaard NL; Zhu Q; Subbarao K
J Infect Dis; 2017 Aug; 216(3):356-365. PubMed ID: 28633457
[TBL] [Abstract][Full Text] [Related]
6. Safety, potential efficacy, and pharmacokinetics of specific polyclonal immunoglobulin F(ab')₂ fragments against avian influenza A (H5N1) in healthy volunteers: a single-centre, randomised, double-blind, placebo-controlled, phase 1 study.
Bal C; Herbreteau CH; Buchy P; Rith S; Zaid M; Kristanto W; Han V; Reynaud C; Granjard P; Lépine B; Durand C; Tambyah PA
Lancet Infect Dis; 2015 Mar; 15(3):285-92. PubMed ID: 25662592
[TBL] [Abstract][Full Text] [Related]
7. Specific polyclonal F(ab')2 neutralize a large panel of highly pathogenic avian influenza A viruses (H5N1) and control infection in mice.
Herbreteau CH; Jacquot F; Rith S; Vacher L; Nguyen L; Carbonnelle C; Lotteau V; Jolivet M; Raoul H; Buchy P; Saluzzo JF
Immunotherapy; 2014; 6(6):699-708. PubMed ID: 24673720
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of oseltamivir therapy in ferrets inoculated with different clades of H5N1 influenza virus.
Govorkova EA; Ilyushina NA; Boltz DA; Douglas A; Yilmaz N; Webster RG
Antimicrob Agents Chemother; 2007 Apr; 51(4):1414-24. PubMed ID: 17296744
[TBL] [Abstract][Full Text] [Related]
9. Protective efficacy of passive immunization with monoclonal antibodies in animal models of H5N1 highly pathogenic avian influenza virus infection.
Itoh Y; Yoshida R; Shichinohe S; Higuchi M; Ishigaki H; Nakayama M; Pham VL; Ishida H; Kitano M; Arikata M; Kitagawa N; Mitsuishi Y; Ogasawara K; Tsuchiya H; Hiono T; Okamatsu M; Sakoda Y; Kida H; Ito M; Quynh Mai L; Kawaoka Y; Miyamoto H; Ishijima M; Igarashi M; Suzuki Y; Takada A
PLoS Pathog; 2014 Jun; 10(6):e1004192. PubMed ID: 24945244
[TBL] [Abstract][Full Text] [Related]
10. Amantadine-oseltamivir combination therapy for H5N1 influenza virus infection in mice.
Ilyushina NA; Hoffmann E; Salomon R; Webster RG; Govorkova EA
Antivir Ther; 2007; 12(3):363-70. PubMed ID: 17591026
[TBL] [Abstract][Full Text] [Related]
11. Intravenous Immunoglobulin Protects Against Severe Pandemic Influenza Infection.
Rockman S; Lowther S; Camuglia S; Vandenberg K; Taylor S; Fabri L; Miescher S; Pearse M; Middleton D; Kent SJ; Maher D
EBioMedicine; 2017 May; 19():119-127. PubMed ID: 28408242
[TBL] [Abstract][Full Text] [Related]
12. Assessing the development of oseltamivir and zanamivir resistance in A(H5N1) influenza viruses using a ferret model.
Hurt AC; Lowther S; Middleton D; Barr IG
Antiviral Res; 2010 Sep; 87(3):361-6. PubMed ID: 20603155
[TBL] [Abstract][Full Text] [Related]
13. Comparison of efficacies of RWJ-270201, zanamivir, and oseltamivir against H5N1, H9N2, and other avian influenza viruses.
Govorkova EA; Leneva IA; Goloubeva OG; Bush K; Webster RG
Antimicrob Agents Chemother; 2001 Oct; 45(10):2723-32. PubMed ID: 11557461
[TBL] [Abstract][Full Text] [Related]
14. Vaccination Is More Effective Than Prophylactic Oseltamivir in Preventing CNS Invasion by H5N1 Virus via the Olfactory Nerve.
Siegers JY; van den Brand JM; Leijten LM; van de Bildt MM; van Run PR; van Amerongen G; Stittelaar KJ; Koopmans MP; Osterhaus AD; Kuiken T; van Riel D
J Infect Dis; 2016 Aug; 214(4):516-24. PubMed ID: 27448390
[TBL] [Abstract][Full Text] [Related]
15. Simvastatin and oseltamivir combination therapy does not improve the effectiveness of oseltamivir alone following highly pathogenic avian H5N1 influenza virus infection in mice.
Belser JA; Szretter KJ; Katz JM; Tumpey TM
Virology; 2013 Apr; 439(1):42-6. PubMed ID: 23453580
[TBL] [Abstract][Full Text] [Related]
16. Cross-protection against lethal H5N1 challenge in ferrets with an adjuvanted pandemic influenza vaccine.
Baras B; Stittelaar KJ; Simon JH; Thoolen RJ; Mossman SP; Pistoor FH; van Amerongen G; Wettendorff MA; Hanon E; Osterhaus AD
PLoS One; 2008 Jan; 3(1):e1401. PubMed ID: 18167560
[TBL] [Abstract][Full Text] [Related]
17. Intranasal vaccination with a plant-derived H5 HA vaccine protects mice and ferrets against highly pathogenic avian influenza virus challenge.
Major D; Chichester JA; Pathirana RD; Guilfoyle K; Shoji Y; Guzman CA; Yusibov V; Cox RJ
Hum Vaccin Immunother; 2015; 11(5):1235-43. PubMed ID: 25714901
[TBL] [Abstract][Full Text] [Related]
18. Pre- and postexposure use of human monoclonal antibody against H5N1 and H1N1 influenza virus in mice: viable alternative to oseltamivir.
Koudstaal W; Koldijk MH; Brakenhoff JP; Cornelissen LA; Weverling GJ; Friesen RH; Goudsmit J
J Infect Dis; 2009 Dec; 200(12):1870-3. PubMed ID: 19911992
[TBL] [Abstract][Full Text] [Related]
19. Low dose influenza virus challenge in the ferret leads to increased virus shedding and greater sensitivity to oseltamivir.
Marriott AC; Dove BK; Whittaker CJ; Bruce C; Ryan KA; Bean TJ; Rayner E; Pearson G; Taylor I; Dowall S; Plank J; Newman E; Barclay WS; Dimmock NJ; Easton AJ; Hallis B; Silman NJ; Carroll MW
PLoS One; 2014; 9(4):e94090. PubMed ID: 24709834
[TBL] [Abstract][Full Text] [Related]
20. Reduced airborne transmission of oseltamivir-resistant pandemic A/H1N1 virus in ferrets.
Hamelin ME; Baz M; Bouhy X; Beaulieu E; Dubé K; Mallett C; Boivin G
Antivir Ther; 2011; 16(5):775-9. PubMed ID: 21817200
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
